secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-125092
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity Trial
--------------------------------------------------------------------------------

- Single 240 mg dose of WVE-007 reduced visceral fat by 14% (placebo-adjusted, p<0.05) at six months.
- WVE-007 showed preservation of lean mass (+2%) and waist circumference reduction (-3%) at six months.
- Phase 2a portion of INLIGHT in higher BMI (35-50 kg/m2) to initiate in 2Q 2026.
- WVE-007 continues to be generally safe and well tolerated with no severe TEAEs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526125092/0001193125-26-125092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526125092/d17239d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-125092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer